Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Outcomes and Prognostic Factors in High-Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Induction
TCTR20190602002Completed
- Sponsor
- Phramongkutklao Hospital and College of Medicine
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of topotecan and cyclophosphamide in neuroblastoma, sponsored by Phramongkutklao Hospital and College of Medicine. Primary endpoints: Treatment response and Prognostic factors for treatment response. Started Jun 2019; status: completed.
02
Drugs
topotecancyclophosphamide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on TCTR20190602002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190602002.